Seragon Biosciences has launched RESTORIN, an advanced nutraceutical for healthy ageing.
RESTORIN integrates a series of patented technologies from Harvard University, Mayo Clinic, and Scripps Research to boost cellular nicotinamide adenine dinucleotide (NAD+) levels and enhance senolytic stimulation.
For decades, the intricate nature of ageing has left scientists with many stones unturned in the field of ageing intervention. The latest research has pinpointed senolytics and NAD+ as key technologies to address this challenge. RESTORIN is a controlled-release senolytic NAD+ booster. It also utilises Seragon's SERC targeted release technology that implements hydrophilic and lipophilic vehicles and a pH-responsive enteric delivery system to enhance ingredient bioavailability.
RESTORIN contains a series of proprietary forms of senolytic agents, NAD+ precursors, and sirtuin-activating compounds (STACs). Senolytics are molecules that target senescent cells - cells that promote ageing and contribute to organ deterioration. NAD+ is a life-preserving coenzyme that enhances cellular energy metabolism and DNA integrity and is the fuel for sirtuins - longevity proteins vital to cellular health.
In the field of ageing, a critical issue to resolve is how to deliver NAD+ precursors in a way that best boosts cellular NAD+ to achieve healthier ageing
"There are many studies that point to these molecules having a positive impact on ageing and ageing-related health conditions, but, so far, no one has been able to combine them at an optimal ratio to achieve a synergistic effect," said David Brown, Ph.D., a senior scientist at Seragon who helped develop RESTORIN. "We've been able to develop advanced forms of these molecules and a series of complex combinations to combat ageing, using the best science we have. This is truly a game-changer."
Decades of research have demonstrated that NAD+ levels significantly decline with ageing, increasing our susceptibility to a myriad of age-related health conditions ranging from diabetes to neurodegeneration. Replenishing NAD+ levels is critical to thwarting ageing. However, it has been challenging to effectively enhance NAD+ at the cellular level through oral delivery.
"In the field of ageing, a critical issue to resolve is how to deliver NAD+ precursors in a way that best boosts cellular NAD+ to achieve healthier ageing," said Dr Brown. "We believe that RESTORIN has achieved best-in-class performance in this regard, which is truly a breakthrough. Especially when you consider recent studies showing an increase in NAD+ can even make immunotherapies against cancer more effective, it's very exciting to be a part of this development."
